Another nail in the coffin for hormone-replacement therapy?

The Lancet

Volumn 374, Issue 9697, 2009, Pages 1217-1218

  Ganti, Apar Kishor ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN RECEPTOR; SOMATOMEDIN C;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; FOLLOW UP; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; POST HOC ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE;

EID: 70349783598     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61571-3     Document Type: Note

References (12)

1. Chlebowski R.T., Schwartz A.G., Wakelee H., et al., for the Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 10.1016/SO140-6736(09)61526-9 published online Sept 20.
2. Schabath M.B., Wu X., Vassilopoulou-Sellin R., Vaporciyan A.A., and Spitz M.R. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 10 (2004) 113-123
3. Ettinger B., Friedman G.D., Bush T., and Quesenberry Jr. C.P. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87 (1996) 6-12
4. Schwartz A.G., Wenzlaff A.S., Prysak G.M., et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 25 (2007) 5785-5792
5. Moore K.A., Mery C.M., Jaklitsch M.T., et al. Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann Thorac Surg 76 (2003) 1789-1795
6. Ganti A.K., Sahmoun A.E., Panwalkar A.W., Tendulkar K.K., and Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 24 (2006) 59-63
7. Huang B., Carloss H., Wyatt S.W., and Riley E. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population. Cancer 115 (2009) 4167-4175
8. Ishibashi H., Suzuki T., Suzuki S., et al. Progesterone receptor in non-small cell lung cancer-a potent prognostic factor and possible target for endocrine therapy. Cancer Res 65 (2005) 6450-6458
9. Omoto Y., Kobayashi Y., Nishida K., et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285 (2001) 340-347
10. Marquez-Garban D.C., Chen H.W., Goodglick L., Fishbein M.C., and Pietras R.J. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci 1155 (2009) 194-205
11. Hays J., Ockene J.K., Brunner R.L., et al., for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348 (2003) 1839-1854
12. Manson J.E., Hsia J., Johnson K.C., et al., for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534